82152 Martinsried/Planegg, de
+49 (89) 864667-150
Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board
Renowned biotech manager to advise Formycon in future / Advisory Board now numbers four highly regarded experts(PresseBox) ( Munich, )
Thomas Siklosi studied chemistry at the Academy of Applied Sciences in Isny. He completed his thesis with distinction at the Institute of Radiochemistry at the Technical University of Munich. He gained his early professional experience in the field of biotechnology at Boehringer Mannheim in the laboratory led by Prof. Hans Ulrich Bergmeyer in Tutzing.
In 1984, he moved to the biotech pioneer Rentschler Arzneimittel in Laupheim and held various roles in the development and production of interferons, later being responsible at Rentschler Biotechnologie, a contract development and manufacturing organization (CDMO), for the provision of biopharmaceutical substances. In cooperation with a leading generic manufacturer, he was responsible as project manager for the technical development of the complex glycoprotein erythropoetin, which received approval as the first epoetin-alfa biosimilar in the EU in the fall of 2007.
In September 2012, Siklosi was appointed to the Board of Management at Rentschler Biopharma SE. As Chief Operating Officer, he was responsible for the Development, GMP Production, Technology, and Quality departments. Siklosi is a Member of the University Council of Biberach University and owns numerous patents in the field of biotechnology.
Dr. Carsten Brockmeyer, board member and CEO of Formycon, said of Siklosi’s appointment: "I'm delighted that we have been able to bring on board Thomas Siklosi, one of the world's most experienced biotech managers. As a man who has been involved with biotechnology right from the start, he has managed numerous biotechnology drugs and biosimilars from cell line development to market maturity over the course of his career. With his many years of in-depth experience in the management of major development and production facilities, Mr. Siklosi will be advising and supporting Formycon AG on its ambitious future projects.”
Alongside Mr. Thomas Siklosi, the Advisory Board is also made up of Prof. Johannes Buchner, Dr. Bernhard Hampl and Dr. Gerhard Schaefer.
This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended.
This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.